DSC Equity Fund – Healthcare A

Reference Data

ISIN AT0000A0XMM2
Valor Number 19994591
Bloomberg Global ID
Fund Name DSC Equity Fund – Healthcare A
Fund Provider Dreyfus Söhne & Cie AG, Banquiers Aeschenvorstadt 16 | Postfach
4051 Basel
Schweiz
Phone: +41 61 286 66 66
Web: https://www.dreyfusbank.ch
Fund Provider Dreyfus Söhne & Cie AG, Banquiers
Representative in Switzerland Dreyfus Söhne & Cie AG, Banquiers
Basel
Distributor(s) Dreyfus Söhne & Cie AG, Banquiers
Basel
Asset Class Equities
EFC Category
Distribution Policy Distribution
Home Country Austria
Issuing Condition The fund does not charge any issuing commission and/or fees (units are issued at the NAV)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** N/A
Peculiarities

Fund Prices

Current Price * 205.71 CHF 19.12.2025
Previous Price * 205.87 CHF 18.12.2025
52 Week High * 230.82 CHF 04.03.2025
52 Week Low * 180.97 CHF 08.08.2025
NAV * 205.71 CHF 19.12.2025
Issue Price * 211.89 CHF 19.12.2025
Redemption Price * 205.71 CHF 19.12.2025
Closing Price *
Indicative Minimum Price
Fund Assets *** 41,523,502
Unit/Share Assets *** 1,745,892
Trading Information SIX

Performance

YTD Performance -5.47% 30.12.2024
19.12.2025
1 month +0.83% 19.11.2025
19.12.2025
3 months +9.39% 19.09.2025
19.12.2025
6 months +7.40% 20.06.2025
19.12.2025
1 year -4.30% 19.12.2024
19.12.2025
2 years -0.29% 19.12.2023
19.12.2025
3 years -8.20% 19.12.2022
19.12.2025
5 years -2.71% 21.12.2020
19.12.2025

Tax Data

Equity Participation Rate in % 96.10
Share of Total Fund Assets in %
Real Estate Rate in % 0.00
ADDI
ADDI Date

Top 10 Holdings ***

iShares MSCI Wld HlthCrSect AdvcdETF$Inc 9.26%
Eli Lilly and Co 7.93%
Johnson & Johnson 6.84%
AstraZeneca PLC 4.32%
AbbVie Inc 3.86%
Abbott Laboratories 3.68%
Merck & Co Inc 3.63%
UnitedHealth Group Inc 3.45%
Thermo Fisher Scientific Inc 3.34%
Roche Holding AG 3.05%
Last data update 30.11.2025

Cost / Risk

TER 1.52%
TER date 31.10.2025
Performance Fee ***
PTR
Max. Management Fee *** 1.50%
Ongoing Charges *** 1.49%
SRRI ***
SRRI date *** 30.11.2025

Breakdowns

Equity Countries ***

Equity Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)